Recurrent prostate cancer refers to cancer that returns after initial treatment, which can happen either locally in the prostate area or a more distant part of the body, indicating metastasis. Recurrence is detected through rising Prostate-Specific Antigen (PSA) levels, a condition known as biochemical recurrence, even when other symptoms are absent. The risk of prostate cancer recurrence depends on multiple factors, including the original cancer’s stage and grade, as well as the completeness and type of treatment initially received. Managing recurrent prostate cancer can involve a range of strategies tailored to the specifics of the recurrence, such as the location and extent of the cancer’s return, previous treatments, and the overall health of the patient. Treatment options for recurrence include hormone therapy, radiation therapy, chemotherapy, surgery to remove the prostate (if not already done), or participation in clinical trials exploring new treatments. The goal of managing recurrent prostate cancer is to control the disease, alleviate symptoms, and maintain quality of life.